Grail Inc

GRAL remains in Stage 2 advancing with a clear higher-highs/higher-lows pattern and price tightly tracking rising EMAs. Despite an overbought tag, there is no exhaustion on RSI or Options Score, and volume supports demand absorption. We engage now on shallow pullbacks into the 9/21 EMA zone to participate in the continuation of the uptrend.

• ↑Q1’26 test volumes jumped 50%, driving screening revenue of $39.8M (+37% YoY).
• ↑Partnerships with major health systems and Epic Aura integration streamline test ordering.
• ↓Negative earnings yield and consensus target imply ~9% downside potential.